AR042648A1 - Derivados de pirazol como inhibidores del factor xa ******* no publicar ********** desistimiento voluntario ********** pasar a alejandra villoldo *********** - Google Patents
Derivados de pirazol como inhibidores del factor xa ******* no publicar ********** desistimiento voluntario ********** pasar a alejandra villoldo ***********Info
- Publication number
- AR042648A1 AR042648A1 ARP030104773A ARP030104773A AR042648A1 AR 042648 A1 AR042648 A1 AR 042648A1 AR P030104773 A ARP030104773 A AR P030104773A AR P030104773 A ARP030104773 A AR P030104773A AR 042648 A1 AR042648 A1 AR 042648A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkylene
- alkyl
- tri
- mono
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000002747 voluntary effect Effects 0.000 title 1
- 125000004122 cyclic group Chemical group 0.000 abstract 10
- 125000002950 monocyclic group Chemical group 0.000 abstract 10
- 125000004429 atom Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000005842 heteroatom Chemical group 0.000 abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 abstract 8
- 229910052717 sulfur Inorganic materials 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- -1 benzoimidazolyl Chemical group 0.000 abstract 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 108010054265 Factor VIIa Proteins 0.000 abstract 4
- 108010074860 Factor Xa Proteins 0.000 abstract 4
- 229940012414 factor viia Drugs 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02028915A EP1433788A1 (en) | 2002-12-23 | 2002-12-23 | Pyrazole-derivatives as factor Xa inhibitors |
| EP03011308A EP1479678A1 (en) | 2003-05-19 | 2003-05-19 | Pyrazole-derivatives as factor xa inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042648A1 true AR042648A1 (es) | 2005-06-29 |
Family
ID=32683809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104773A AR042648A1 (es) | 2002-12-23 | 2003-12-22 | Derivados de pirazol como inhibidores del factor xa ******* no publicar ********** desistimiento voluntario ********** pasar a alejandra villoldo *********** |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1581523B1 (enExample) |
| JP (1) | JP4585448B2 (enExample) |
| AR (1) | AR042648A1 (enExample) |
| AT (1) | ATE444292T1 (enExample) |
| AU (1) | AU2003292218A1 (enExample) |
| BR (1) | BR0317659A (enExample) |
| CA (1) | CA2511321A1 (enExample) |
| DE (1) | DE60329529D1 (enExample) |
| IL (1) | IL169323A0 (enExample) |
| MX (1) | MXPA05006200A (enExample) |
| PE (1) | PE20040925A1 (enExample) |
| TW (1) | TW200505914A (enExample) |
| WO (1) | WO2004056815A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| ITMI20041032A1 (it) | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
| DE102004047255A1 (de) * | 2004-09-29 | 2006-04-13 | Merck Patent Gmbh | Prolinderivate |
| JP4912314B2 (ja) | 2004-10-26 | 2012-04-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 因子Ｘａ化合物 |
| US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| CN101087762A (zh) * | 2004-10-29 | 2007-12-12 | 先灵公司 | 作为抗病毒剂的取代的5－甲酰胺吡唑和[1,2,4]三唑 |
| EP1833819A1 (en) | 2004-12-30 | 2007-09-19 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
| EP1724269A1 (en) * | 2005-05-20 | 2006-11-22 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors |
| WO2007002559A1 (en) * | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
| US8399442B2 (en) | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
| WO2008001115A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea |
| WO2009080227A2 (en) * | 2007-12-26 | 2009-07-02 | Sanofi-Aventis | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| EP2238128B1 (en) * | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
| JP5432890B2 (ja) | 2008-04-04 | 2014-03-05 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
| EP2276761B1 (en) * | 2008-04-23 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
| AR079967A1 (es) | 2010-01-26 | 2012-02-29 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos |
| RU2639876C2 (ru) | 2010-03-30 | 2017-12-25 | Версеон Корпорейшн | Мультизамещенные ароматические соединения в качестве ингибиторов тромбина |
| TWI523844B (zh) | 2011-01-26 | 2016-03-01 | 賽諾菲公司 | 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途 |
| AR085013A1 (es) | 2011-01-26 | 2013-08-07 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas |
| HRP20160047T1 (hr) | 2011-07-26 | 2016-02-12 | Sanofi | Derivati 3-heteroaroilamino-propionske kiseline i njihova upotreba kao lijekova |
| BR112014001587A2 (pt) | 2011-07-26 | 2017-02-14 | Sanofi Sa | derivados de ácido 3-(tiazol-4-carbonil)- ou 3-(tiazol-2-carbonil) amino-propiônico substituídos e seu uso como produtos farmacêuticos |
| WO2013072327A1 (en) | 2011-11-14 | 2013-05-23 | Sanofi | Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases |
| WO2013072328A1 (en) | 2011-11-14 | 2013-05-23 | Sanofi | Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases |
| US9951025B2 (en) | 2013-03-15 | 2018-04-24 | Verseon Corporation | Halogenopyrazoles as inhibitors of thrombin |
| MX373964B (es) | 2013-03-15 | 2020-07-13 | Verseon Corp | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. |
| AR095764A1 (es) | 2013-03-28 | 2015-11-11 | Sanofi Sa | Derivados de ácido biaril-propiónico y su uso como productos farmacéuticos |
| SG11201506292XA (en) | 2013-03-28 | 2015-09-29 | Sanofi Sa | Biaryl-propionic acid derivatives and their use as pharmaceuticals |
| EP3184095A1 (en) | 2013-05-23 | 2017-06-28 | IP Gesellschaft für Management mbH | Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
| US10189810B2 (en) | 2014-09-17 | 2019-01-29 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| SI3261639T1 (sl) | 2015-02-27 | 2023-01-31 | Verseon International Corporation | Substituirane pirazolne spojine kot zaviralci serinskih proteaz |
| WO2016202756A1 (en) | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds |
| JOP20190192A1 (ar) * | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| NZ504013A (en) * | 1997-11-28 | 2002-02-01 | Lg Chemical Ltd | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof |
| BR9813835A (pt) * | 1997-12-22 | 2000-10-10 | Du Pont Pharm Co | Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica |
| SI1140941T1 (en) * | 1998-12-23 | 2005-04-30 | Bristol-Myers Squibb Pharma Company | Nitrogen containing heterobicycles as factor xa inhibitors |
| ATE268766T1 (de) * | 1999-07-16 | 2004-06-15 | Bristol Myers Squibb Pharma Co | Stickstoff enthaltende heterobicyclen als factor xa inhibitoren |
| CA2385589A1 (en) * | 1999-09-17 | 2001-03-22 | Bing-Yan Zhu | Inhibitors of factor xa |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| EP1226123A1 (en) * | 1999-11-03 | 2002-07-31 | Du Pont Pharmaceuticals Company | Cyano compounds as factor xa inhibitors |
| AU2001268711A1 (en) * | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| WO2002000651A2 (en) * | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| US6750225B2 (en) * | 2001-04-18 | 2004-06-15 | Bristol-Myers Squibb Pharms Company | 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors |
-
2003
- 2003-12-10 AT AT03767776T patent/ATE444292T1/de not_active IP Right Cessation
- 2003-12-10 JP JP2005502535A patent/JP4585448B2/ja not_active Expired - Fee Related
- 2003-12-10 WO PCT/EP2003/013979 patent/WO2004056815A1/en not_active Ceased
- 2003-12-10 MX MXPA05006200A patent/MXPA05006200A/es unknown
- 2003-12-10 CA CA002511321A patent/CA2511321A1/en not_active Abandoned
- 2003-12-10 AU AU2003292218A patent/AU2003292218A1/en not_active Abandoned
- 2003-12-10 EP EP03767776A patent/EP1581523B1/en not_active Expired - Lifetime
- 2003-12-10 BR BR0317659-2A patent/BR0317659A/pt not_active IP Right Cessation
- 2003-12-10 DE DE60329529T patent/DE60329529D1/de not_active Expired - Lifetime
- 2003-12-19 TW TW092136068A patent/TW200505914A/zh unknown
- 2003-12-22 AR ARP030104773A patent/AR042648A1/es unknown
-
2004
- 2004-01-05 PE PE2004000015A patent/PE20040925A1/es not_active Application Discontinuation
-
2005
- 2005-06-21 IL IL169323A patent/IL169323A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004056815A1 (en) | 2004-07-08 |
| JP2006511608A (ja) | 2006-04-06 |
| BR0317659A (pt) | 2005-12-06 |
| ATE444292T1 (de) | 2009-10-15 |
| EP1581523B1 (en) | 2009-09-30 |
| TW200505914A (en) | 2005-02-16 |
| EP1581523A1 (en) | 2005-10-05 |
| DE60329529D1 (de) | 2009-11-12 |
| MXPA05006200A (es) | 2005-08-19 |
| CA2511321A1 (en) | 2004-07-08 |
| AU2003292218A1 (en) | 2004-07-14 |
| JP4585448B2 (ja) | 2010-11-24 |
| PE20040925A1 (es) | 2004-12-24 |
| IL169323A0 (en) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042648A1 (es) | Derivados de pirazol como inhibidores del factor xa ******* no publicar ********** desistimiento voluntario ********** pasar a alejandra villoldo *********** | |
| JP6684552B2 (ja) | 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン | |
| ES2750153T3 (es) | Compuestos y métodos para tratamiento antiviral | |
| ES2787704T3 (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis B | |
| AU2009303602B2 (en) | Compounds and methods of use | |
| ES2713624T3 (es) | Derivados de oxopiridina sustituidos | |
| ES2437595T3 (es) | Derivados de tiazol usados como inhibidores de la PI 3 quinasa | |
| EP2730572B1 (en) | Spiro compounds as hepatitis c virus inhibitors | |
| RU2001132635A (ru) | Производные пиперидина, применимые в качестве антагонистов сс R5 | |
| ES2712886T3 (es) | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa | |
| CA2481369A1 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease | |
| CA2598294A1 (en) | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative | |
| CA2426457A1 (en) | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | |
| WO2005011656A3 (en) | Pyridyl derivatives and their use as therapeutic agents | |
| CN102869657A (zh) | 用于治疗或预防黄病毒感染的类似物 | |
| HRP20211728T1 (hr) | Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi | |
| JP2019528291A (ja) | 抗生化合物 | |
| HRP20110441T1 (hr) | Derivati 2-benzilpiridazinona kao inhibitori met kinaze | |
| PT1846424E (pt) | Inibidores de proteassomas e seus métodos de utilização | |
| BR112014030284B1 (pt) | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| JP2018514544A5 (enExample) | ||
| JP2013529684A (ja) | フラビウイルス感染の処置または予防のための化合物および方法 | |
| AU2019291488B2 (en) | N-substituted tetrahydrothienopyridine derivatives and uses thereof | |
| WO2015161830A1 (en) | Heteroaromatic derivatives and pharmaceutical applications thereof | |
| FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |